Last updated: February 15, 2026
What is the current market status of drug NDC 00904-6294?
NDC 00904-6294 corresponds to Mifeprex (mifepristone) tablets, used for medical termination of early pregnancy (up to 10 weeks gestation). Its market landscape has evolved following recent regulatory, policy, and market dynamics, particularly in the United States.
How is the market for mifepristone structured?
Regulatory environment
- The FDA approved Mifeprex in 2000 under the Risk Evaluation and Mitigation Strategy (REMS) program.
- The REMS restricts distribution to certified facilities and prescribers.
- In 2021, the FDA removed the in-person dispensing requirement amid the COVID-19 pandemic, allowing pharmacies to dispense mifepristone remotely in some states.
Market size and key players
- Estimates suggest the U.S. market for medical abortion drugs was valued at approximately $250 million in 2022.
- Major players include:
- Danco Laboratories (original manufacturer of Mifeprex)
- Online pharmacy providers
- Competing generic formulations as they enter the market
Supply chain and distribution
- Distribution centers around certified clinics, hospitals, and pharmacies.
- Several states restrict or ban telemedicine-based dispensing, influencing market access.
What are the price projections for NDC 00904-6294?
Current pricing dynamics
- Average retail price per Mifeprex 200 mg tablet: approximately $70–$90 (per 3-tablet pack).
- Total costs for a standard medical abortion: $300–$600, considering consultation, oversight, and medication.
Future pricing trends
- As generic versions enter the market, prices are expected to decline by 20-40% over the next 2-3 years.
- The potential for price stabilization hinges on regulatory developments, supply chain stability, and state-level restrictions.
| Timeframe |
Price Expectation |
Drivers |
| 1 Year |
Slight decline |
Increased generic competition, stable demand |
| 3 Years |
20-40% drop |
Broader market penetration, policy changes |
| 5 Years |
Possible stabilization |
Regulatory adjustments, expanded telemedicine |
Key factors influencing prices
- Regulatory changes: Expansion of REMS protocols or removals could alter supply and pricing.
- Market entry: Generic manufacturers reducing prices to gain market share.
- Policy shifts: States restricting access could reduce demand and influence pricing dynamics.
What are the competitive considerations?
Regulatory challenges
- While FDA relaxed some restrictions during the pandemic, ongoing legal appeals and state-level bans impact market access.
- Potential reintroduction of restrictions or new legislations can affect supply and pricing.
Market entrance barriers
- High regulatory compliance costs for generic manufacturers.
- Distribution network limitations due to legal and logistical barriers.
Price elasticity
- Moderate elasticity: Price changes influence demand, but access restrictions heavily impact actual market volume.
Summary: Market outlook and price projections
The market for NDC 00904-6294, primarily composed of Mifeprex, is characterized by limited pricing flexibility in the short term due to regulatory factors but faces downward pressure from generic competition over the medium to long term. Price declines of 20-40% are anticipated within three years, assuming current trends persist. Policy developments and legal battles remain key uncertainties.
Key Takeaways
- The U.S. market for mifepristone is approximately $250 million annually.
- Regulatory changes, including telemedicine access, influence supply and pricing.
- Generic competition is expected to reduce prices significantly within three years.
- Price declines hinge on market access, legal frameworks, and supply chain stability.
- Ongoing legal and legislative developments are the primary uncertainties affecting market dynamics.
FAQs
1. How do regulatory restrictions impact the price of mifepristone?
Restrictions limit supply channels, potentially increasing prices due to limited competition. Conversely, easing restrictions promotes market entry and price competition, driving prices down.
2. What are the main factors that could alter future price projections?
Key factors include legislative changes, FDA policy modifications, the emergence of generic competitors, and interstate legal disputes.
3. When are generic versions of mifepristone expected to enter the market?
Generics are anticipated to enter within 2-3 years, depending on patent litigation and regulatory approvals.
4. How does telemedicine influence the market for NDC 00904-6294?
Telemedicine can increase access, boost demand, and potentially lead to price reductions, provided legal barriers are addressed.
5. What is the potential impact of legal challenges on the market?
Legal battles may restrict or expand access, causing volatility in demand and pricing.
References
- U.S. Food and Drug Administration. Mifepristone REMS. https://www.fda.gov
- MarketWatch. Mifepristone market size and forecasts. 2022.
- IQVIA. U.S. pharmaceutical market insights. 2022.
- Guttmacher Institute. Abortion technology and legislative landscape. 2022.
- Reuters. Legal developments affecting abortion medication. 2023.
